Pharmacosmos Group, a developer of treatments for patients suffering from iron deficiency and iron deficiency anemia, has bought AbFero Pharmaceuticals, Inc.

ApFero is a Boston-based, privately owned clinical stage pharmaceutical company focused on treating diseases of iron overload. The firm will acquire all assets of AbFero under a purchase agreement for consideration of up to $225 million.

Given Pharmacosmos’s research focus and expertise within iron metabolism and its international commercial presence, the acquisition of AbFero constitutes a perfect strategic fit,” added Lars Christensen, CEO of Pharmacosmos.

“As a leader in iron metabolism disorders, Pharmacosmos is uniquely positioned to realize the full potential of our chelation platform,” said AbFero CEO and co-founder Thomas Neenan.